Clinical study of mifepristone with or without tamoxifen in the treatment of leiomyoma
- VernacularTitle:米非司酮配伍与不配伍三苯氧胺治疗子宫肌瘤的临床观察
- Author:
Lijun YANG
;
Jiaxue WEI
- Publication Type:Journal Article
- From:Chinese Journal of Practical Gynecology and Obstetrics
2001;17(3):145-146
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy of mifepristone with or without tamoxifen in the treatment of leiomyomas. Methods173 symptomatic patients with leiomyomas were divided into 2 groups randomly. Group A (88cases) received mifepristone 25mg per day;Group B(85 cases) received mifepristone per day combined with tamoxifen l0mg twice a day from the first day of menstrul cycle for three months. Leiomyoma and uterine size were measured by B ultrasound, the changes of endometrium were examined pathologically. Estrogen and progesterone levels, hemoglobin and liver renal function were all measured, meanwhile, adverse effects of drugs were assessed. ResultsAll the patients in the 2 groups were amenorrhea with increased hemoglobin, the level of estrogen and progesterone remained in the early stage of proliferation phase. The uterus and leiomyoma sizes in two groups both reduced, but those in group B reduced less significantly(P＜0.01). Adverse effects showed similarity and needed no special control. ConclusionsBoth mifepristone and mifepristone combined with tamoxifen show good efficacy in the treatment of leiomyoma, but mifepristone combined with tamoxifen is more suitable.
